 eYugoslavia.com | Biogen Idec and Abbott Present Positive Data for Daclizumab HYP from Select ... Victoria Times Colonist Today Biogen Idec (NASDAQ: BIIB) and Abbott (NYSE: ABT) announced additional results from the SELECT Phase 2b trial, the first of two registrational studies designed to evaluate the investigational compound daclizumab high-yield process (DAC HYP) in ... Biogen Idec, Abbott Say SELECT Phase 2B Trial For RRMS Compound Met Primary Goal Biogen Idec and Abbott Present Positive Data for Daclizumab HYP from Select ... |
